DCs, pulsed with peptides derived from the EWSR1–FLI1 fusion protein and adjuvant intravenous compounds that stimulate the immune system such as IL-2, were used in clinical trials but tumor regression was time-limited [112]. Here, FLI1 is linked to neoplasm.